According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...

Carte­sian Ther­a­peu­tics said its au­tol­o­gous CAR-T ther­a­py has shown “sus­tained ben­e­fits” in peo­ple with a rare au­toim­mune dis­ease, ac­cord­ing to the lat­est ...

in patients with generalized myasthenia gravis (gMG) were presented during the Late-Breaking Science Session at the American Academy of Neurology (AAN) Annual Meeting 2025 in San Diego ...

Interim results from the ME&MGopen study demonstrate strong adherence, high usability, and meaningful clinical associations in myasthenia gravis The ME&MGopenTM study highlights the potential ...

Descartes-08 represents a flagship advancement in Cartesian’s mission to transform the treatment landscape for autoimmune diseases, with this latest data reinforcing its potential as a safe and ...

ABOUT GENERALIZED MYASTHENIA GRAVIS (gMG) Myasthenia gravis (MG) is an autoantibody disease in which the immune system mistakenly makes antibodies (e.g., anti-acetylcholine receptor [AChR], anti ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open-label extension ...

Jan-Mar;14(1):7-16. doi: 10.25122/jml-2020-0145 10 Dresser, Laura et al. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. Journal of clinical medicine vol. 10,11 ...